Is the Eutos Long Term Survival (ELTS) Score a Useful Marker to Predict Outcome in Children with Newly Diagnosed Chronic Myeloid Leukemia (CML) in Chronic Phase (CP)? the Experience of the International Registry of Childhood CML

被引：0

作者：

Millot, Frederic ^{[1
]}

De Keizer, Joe ^{[2
]}

Metzler, Markus ^{[3
]}

Suttorp, Meinolf ^{[4
]}

Sedlacek, Petr ^{[5
]}

Luesink, Maaike ^{[6
]}

Cheng, Frankie W. T. ^{[7
]}

Kalwak, Krzysztof ^{[8
,9
]}

Lausen, Birgitte ^{[10
]}

Jakovljevic, Gordana ^{[11
]}

De Moerloose, Barbara ^{[12
]}

Dworzak, Michael ^{[13
]}

Borisevich, Marina ^{[14
]}

Yajima, Julia ^{[15
]}

Ampatzidou, Mirella ^{[16
]}

Farah, Roula ^{[17
]}

Kaiserova, Emilia ^{[18
]}

Guenes, Adalet Meral ^{[19
]}

Baruchel, Andre ^{[20
]}

机构：

[1] CHU Poitiers, Inserm, CIC 1402, Poitiers, France

[2] Inserm, CIC 1402, Poitiers, France

[3] Univ Hosp Erlangen, Dept Pediat & Adolescent Med, Erlangen, Germany

[4] Tech Univ, Fac Med, Pediat Hematol & Oncol, Dresden, Germany

[5] Charles Univ Prague, Univ Hosp Motol, Dept Pediat Hematol Oncol, Prague, Czech Republic

[6] Princess Maxima Ctr Pediat Oncol, Dutch Childhood Oncol Grp, Utrecht, Netherlands

[7] Prince Wales Hosp, Dept Pediat, Hong Kong, Peoples R China

[8] Wroclaw Med Univ, Dept Pediat Hematol Oncol, Wroclaw, Poland

[9] Wroclaw Med Univ, BMT, Wroclaw, Poland

[10] Univ Copenhagen, Dept Pediat & Adolescent Med, Rigshosp, Copenhagen, Denmark

[11] Childrens Hosp, Dept Pediat Hematol Oncol, Zagreb, Croatia

[12] Ghent Univ Hosp, Dept Pediat Hematol Oncol, Ghent, Belgium

[13] St Anna Childrens Canc Res Inst, Vienna, Austria

[14] Belarusian Res Ctr Pediat Oncol Hematol & Immunol, Minsk, BELARUS

[15] Ctr Infantil Boldrini, Sao Paulo, Brazil

[16] Aghia Sophia Childrens Hosp, Dept Pediat Hematol Oncol, Athens, Greece

[17] LAU Med Ctr Rizk Hosp, Dept Pediat, Beirut, Lebanon

[18] Univ Childrens Hosp, Dept Pediat Oncol, Bratislava, Slovakia

[19] Hosp Gorukle, Pediat Hematol & Oncol, Bursa, Turkiye

[20] Robert Debre Hosp, Dept Pediat Hematol, Paris, France

来源：

BLOOD | 2023年 / 142卷

关键词：

D O I：

10.1182/blood-2023-173810

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

引用

下载

页数：4

共 50 条

[31] Long-term outcome of tyrosine kinase inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase
Zheng, Yong-Zhi
Li, Jian
Chen, Cai
Zheng, Hao
Fu, Dan-Hui
Hu, Jian-Da
CHINESE MEDICAL JOURNAL, 2021, 134 (24) : 3009 - 3011
[32] Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study
Breccia, Massimo
Pregno, Patrizia
Castagnetti, Fausto
Bonifacio, Massimiliano
Tiribelli, Mario
Gozzini, Antonella
Scortechini, Anna Rita
Luciano, Luigiana
Martino, Bruno
Stagno, Fabio
Caocci, Giovanni
La Barba, Gaetano
Pizzuti, Michele
Ciccone, Giovannino
Saglio, Giuseppe
Specchia, Giorgina
LEUKEMIA, 2021, 35 (06) : 1814 - 1816
[33] Early Response (Molecular and Cytogenetic) and Long-Term Outcomes in Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase (CML-CP): Exploratory Analysis of DASISION 3-Year Data
Saglio, Giuseppe
Kantarjian, Hagop M.
Shah, Neil
Jabbour, Elias J.
Quintas-Cardama, Alfonso
Luis Steegmann, Juan
Boque, Concepcion
Chuah, Charles
Pavlovsky, Carolina
Mayer, Jiri
Ukropec, Jon
Wildgust, Mark
Hochhaus, Andreas
BLOOD, 2012, 120 (21)
[34] EUTOS LONG-TERM SURVIVAL SCORE (ELTS) BETTER DEFINES THE RISK OF DEATH FOR CHRONIC MYELOID LEUKEMIA PATIENTS TREATED OUTSIDE OF CLINICAL TRIALS
Molica, M.
Canichella, M.
Fegatelli, D. Alunni
Colafigli, G.
Massaro, F.
Latagliata, R.
Foa, R.
Breccia, M.
HAEMATOLOGICA, 2017, 102 : 83 - 83
[35] Eutos long-term survival score discriminates different Sokal score categories in chronic myeloid leukemia patients, showing better survival prediction. Analysis of the GIMEMA CML observational study
Massimo Breccia
Patrizia Pregno
Fausto Castagnetti
Massimiliano Bonifacio
Mario Tiribelli
Antonella Gozzini
Anna Rita Scortechini
Luigiana Luciano
Bruno Martino
Fabio Stagno
Giovanni Caocci
Gaetano La Barba
Michele Pizzuti
Giovannino Ciccone
Giuseppe Saglio
Giorgina Specchia
Leukemia, 2021, 35 : 1814 - 1816
[36] Beneficial effects of cytogenetic and molecular response on long-term outcome in patients with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM): Update from the IRIS study.
Simonsson, B
BLOOD, 2005, 106 (11) : 52A - 52A
[37] Interim analysis of a multicenter trial of high dose (HD) imatinib in newly diagnosed early chronic phase (CP) patients (pt) with chronic myeloid leukemia (CML).
Cortes, J
Giles, F
Salvado, AJ
McDougall, K
Radich, J
Albitar, M
Powell, BL
Goldberg, S
Kantarjian, HM
BLOOD, 2005, 106 (11) : 316A - 316A
[38] COMPARATIVE EFFICACY OF IMATINIB, DASATINIB AND NILOTINIB FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): A META-ANALYSIS AND INDIRECT COMPARISON
Park, J.
Kwon, H.
Shin, M.
Shin, S.
Lee, J. Y.
VALUE IN HEALTH, 2015, 18 (07) : A433 - A433
[39] CONTINUED SUPERIORITY OF NILOTINIB VS IMATINIB IN PATIENTS WITH NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA IN CHRONIC PHASE (CML-CP): ENESTND BEYOND 1 YEAR
Hochhaus, A.
Lobo, C.
Pasquini, R.
Clark, R.
Kim, D. W.
Issaragrisil, S.
le Coutre, P.
Reiffers, J.
Kantarjian, H.
Saglio, G.
Edrich, P.
Hoenekopp, A.
Gallagher, N.
Larson, R.
Hughes, T.
HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2010, 95 : 459 - 459
[40] Update on lower-dose dasatinib 50 mg daily as frontline therapy in newly diagnosed chronic phase chronic myeloid leukemia (CML-CP).
Naqvi, Kiran
Jabbour, Elias
Skinner, Jeffrey A.
Anderson, Kristin N.
Yilmaz, Musa
Jain, Nitin
Ferrajoli, Alessandra
Bose, Prithviraj
Thompson, Philip A.
Alvarado, Yesid
Takahashi, Koichi
Burger, Jan Andreas
Borthakur, Gautam
Estrov, Zeev
Pemmaraju, Naveen
Paul, Shilpa
Dellasala, Sara
Cortes, Jorge E.
Kantarjian, Hagop M.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)

← 1 2 3 4 5 →